ENTITY
Daiichi Sankyo

Daiichi Sankyo (4568 JP)

137
Analysis
Health CareJapan
Daiichi Sankyo Co, Ltd is a holding company established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
more
bullishDaiichi Sankyo
01 Nov 2024 08:30

Daiichi Sankyo (4568 JP): Enhertu Drives Beat-And-Raise Q2FY25; Pipeline Progress Boosts Visibility

​Daiichi Sankyo beats expectations in Q2FY25 with revenue up 19% driven by Enhertu sales. The company raises FY25 guidance due to strong global...

Logo
169 Views
Share
bullishDaiichi Sankyo
16 Oct 2024 15:22

Daiichi Sankyo (4568 JP) Valuation Update – Are We There Yet?

The “priced for perfection scenario” is unwinding and the valuation is become more palatable. We recommend buying into weakness.

Logo
daaimon
212 Views
Share
bullishDaiichi Sankyo
10 Sep 2024 14:19

Daiichi Sankyo (4568 JP): Starts FY25 on Firm Note; Enhertu Flying Higher Highs; Guidance Reaffirmed

Daiichi Sankyo shares plunged due to mixed clinical trial result of Dato-DXd in lung cancer. While Dato-DXd showed a 2.3-month improvement in...

Logo
486 Views
Share
bullishDaiichi Sankyo
02 May 2024 12:00

Daiichi Sankyo (4568 JP) – We like the Focus on Oncology but Look for a Better Entry Point

Daiichi Sankyo has increased focus on high growth oncology and entered into a potentially very lucrative deal with Merck. We like the company, we...

Logo
daaimon
211 Views
Share
bullishDaiichi Sankyo
25 Apr 2024 18:16

Daiichi Sankyo (4568 JP): FY24 Ends on Strong Note; Initiates FY25 Guidance; ¥200B Buyback Announced

Daiichi Sankyo announced better-than-expected Q4 result, with all key parameters exceeding guidance. For FY25, the company expects 9% revenue and...

Logo
314 Views
Share
x